Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04611581
Other study ID # 2020-01777
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 1, 2021
Est. completion date December 2025

Study information

Verified date November 2022
Source University Hospital Inselspital, Berne
Contact Deborah Amstutz, MSc Psy
Phone +41 31 664 05 67
Email deborah.amstutz@insel.ch
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this project is to measure behavioural disorders in Parkinson's disease (PD) patients in a more objective way, in order to facilitate the detection of those symptoms and improve the treatment of non-motor symptoms in Parkinson's disease.


Description:

Apathy and impulse control disorders (ICDs) are frequent non-motor symptoms of PD and negatively affect the quality of life of patients. Although healthcare professionals have begun to understand the extent of the problem faced by those suffering apathy or ICDs, accurate diagnosis is still difficult, as behavioural symptoms are often multidimensional, develop gradually over the course of months and clinical staff have to rely on the self-report of the patient or the report of a family member to assess them. To overcome this issue, the investigators aim to use information and communication technologies to measure apathy and hyperdopaminergic behaviours in PD patients in an objective way, with the ultimate goal of improving the management of PD patients. To do so, the investigators will use three computer-based tasks that measure effort-based decision making, reward processing and emotion processing in PD patients, and assess motor, cognitive and neuropsychiatric symptoms in parallel with scales and tests. In some select patients, motor symptoms and activity patterns will be monitored with an in-home sensor system before and after deep brain stimulation (DBS), and the above mentioned procedures will be repeated in a longitudinal design.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosed with Parkinson's disease. - Able to understand instructions and provide informed consent. - Native speaking or proficient French or German - Montreal Cognitive Assessment (MoCA) with score = 22 - Ability to manipulate handheld dynamometers - For sensor part only: planned DBS-surgery Exclusion Criteria: - Disease affecting the brain other than Parkinson's disease - Suffering from or diagnosed with ongoing psychiatric illnesses - Severe somatic illnesses leading to reduced life expectancy - Severe physical disability leading to impairment in basic functional activities - Participation in a pharmacological study - Inability to provide informed consent (legal guardianship)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Switzerland Insel Gruppe AG University Hospital of Bern Bern

Sponsors (3)

Lead Sponsor Collaborator
University Hospital Inselspital, Berne University of Bern, University of Oxford

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Performance in an effort-based decision making task (Apple Tree Paradigm) Decision (yes/no) Visit 1 (only visit for most patients; for DBS patients 1-3 months before DBS-surgery)
Primary Performance in an effort-based decision making task (Apple Tree Paradigm) Decision (yes/no) Visit 2 (only for DBS patients; 4-6 months after DBS-surgery)
Primary Performance in an effort-based decision making task (Apple Tree Paradigm) Decision (yes/no) Visit 3 (only for DBS patients; 11-13 months after DBS-surgery)
Primary Performance in a reward task Pupil diameter (in mm) Visit 1 (only visit for most patients; for DBS patients 1-3 months before DBS-surgery)
Primary Performance in a reward task Pupil diameter (in mm) Visit 2 (only for DBS patients; 4-6 months after DBS-surgery)
Primary Performance in a reward task Pupil diameter (in mm) Visit 3 (only for DBS patients; 11-13 months after DBS-surgery)
Primary Performance in an emotion processing task Pupil diameter (in mm) Visit 1 (only visit for most patients; for DBS patients 1-3 months before DBS-surgery)
Primary Performance in an emotion processing task Pupil diameter (in mm) Visit 2 (only for DBS patients; 4-6 months after DBS-surgery)
Primary Performance in an emotion processing task Pupil diameter (in mm) Visit 3 (only for DBS patients; 11-13 months after DBS-surgery)
Primary Change in overall activity from Baseline to 12 months after DBS-surgery Changes in overall activity patterns related to motivated behaviours (measured in minutes per day) will be deducted from collected from in-home sensor data using signal processing and machine learning algorithms In-home sensor measurements will be collected from 1-3 months before DBS-surgery until 12 months after DBS-surgery
See also
  Status Clinical Trial Phase
Completed NCT02915848 - Long-term Stability of LFP Recorded From the STN and the Effects of DBS
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Terminated NCT02688465 - Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Phase 4
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Active, not recruiting NCT04006210 - Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Phase 3
Completed NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Phase 3
Completed NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Phase 3
Recruiting NCT06002581 - Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease N/A
Completed NCT02236260 - Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation N/A
Completed NCT00529724 - Body Weight Gain, Parkinson, Subthalamic Stimulation Phase 2
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Completed NCT03703570 - A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations Phase 2
Completed NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures N/A
Completed NCT02837172 - Diagnosis of PD and PD Progression Using DWI
Not yet recruiting NCT04046276 - Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease N/A
Recruiting NCT02952391 - Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol N/A
Active, not recruiting NCT02937324 - The CloudUPDRS Smartphone Software in Parkinson's Study. N/A
Terminated NCT02924194 - Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease N/A
Completed NCT02927691 - Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial Phase 2